Summary of Study ST002497
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001612. The data can be accessed directly via it's Project DOI: 10.21228/M8BB1T This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002497 |
Study Title | Postnatal hyperglycemia alters amino acid profile in retinas |
Study Summary | Nutritional deprivation occurring in most preterm infants postnatally, can induce hyperglycemia, a significant and independent risk factor for suppressing physiological retinal vascularization (Phase I retinopathy of prematurity (ROP)), leading to compensatory but pathological neovascularization. Amino acid supplementation reduces retinal neovascularization in mice. Little is known about amino acid contribution to Phase I ROP. Significant changes in retinal amino acids (including most decreased L-leucine, L-isoleucine and L-valine) were found in mice modeling hyperglycemia-associated Phase I ROP, and parenteral (i.p.) L-isoleucine suppressed physiological retinal vascularization. In premature infants, severe ROP was associated with a higher mean intake of parenteral versus enteral amino acids in the first two weeks of life after adjustment for treatment group, gestational age at birth, birth weight and sex. The number of days with parenteral amino acids support independently predicted severe ROP. Further understanding and modulating amino acids may help improve nutritional intervention and prevent Phase I ROP |
Institute | Boston Childrens Hospital |
Last Name | Fu |
First Name | Zhongjie |
Address | 1 Blackfan Circle, Boston, MA 02114 |
Zhongjie.Fu@childrens.harvard.edu | |
Phone | 617-919-2534 |
Submit Date | 2023-02-16 |
Raw Data Available | Yes |
Raw Data File Type(s) | mzXML |
Analysis Type Detail | LC-MS |
Release Date | 2023-03-22 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
Analysis ID | AN004101 |
---|---|
Analysis type | MS |
Chromatography type | HILIC |
Chromatography system | Thermo Ultimate 3000 |
Column | SeQuant ZIC-pHILIC (150 x 2.1mm, 5um) |
MS Type | ESI |
MS instrument type | Orbitrap |
MS instrument name | Thermo Q Exactive HF hybrid Orbitrap |
Ion Mode | UNSPECIFIED |
Units | Absolute Intensity |
MS:
MS ID: | MS003848 |
Analysis ID: | AN004101 |
Instrument Name: | Thermo Q Exactive HF hybrid Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | Initial data analysis (metabolite identification & quantification) was performed by the NYU metabolomics facility 3,9-11. Subsequent downstream bioinformatic analysis was performed using MetaboAnalyst R-based statistical and pathway analysis (v5.0) as described by Petrova et al. 12 using updates as described by Pang et al. 13. Differences in metabolite levels between groups were assessed using unpaired t test and considered statistically significant if P<0.05. For pathway analysis SMPDB database was reviewed, applying Fisher’s Exact Test for mapping. Only metabolites meeting P-value criteria were loaded for the analysis. |
Ion Mode: | UNSPECIFIED |